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A b s t r a c t  
This work assesses the stability and quality of Ciprofloxacin hydrochloride tablets after subjection to 
accelerated stability conditions of sunlight, temperature of 40±10C, 75% relative humidity, and UV 
light of 365 nm for 4 hours each day. This study was performed at time zero and at 4-day intervals 
for a period of 45 days (that is, days 0, 4, 8, 12…40, 44) according to the International Conference 
on Harmonization (ICH) accelerated aging conditions and the results obtained were subjected to 
statistical analysis. The results showed that with increasing time there was a gradual reduction in the 
dissolution rate with the tablets exposed to all four storage conditions failing the test on day 44 
where they had less than 80 % release of the label claim. For content of Ciprofloxacin Hydrochloride, 
only those tablets exposed to UV light passed the test for all 44 days as they had a minimum of 
96.83 % content on the 44th day. At day 0, all the tablets assayed passed this test, having a 
ciprofloxacin content of 99.43 %. For those tablets subjected to the other storage conditions 
including temperature of 40±10C, 75 % relative humidity and sunlight, they had ciprofloxacin content 
of 70.22 %, 71.50 %, and 78.36 % respectively. The results further, indicated that the storage 
conditions used in the study had a greater impact on the dissolution behavior and content of the 
Ciprofloxacin tablets than they did on the physical stability (hardness, uniformity of weight, 
disintegration).  
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Introduction 
Ciprofloxacin and other fluoroquinolones are valued for their broad 
spectrum of activity, excellent tissue penetration and their 
availability in both oral and intravenous formulations. Among the 
flouroquinolones however, Ciprofloxacin is the most widely used of 
the second generation quinolone antibiotics and is one of the most 
potent [4]. It is very effective, especially used as a better alternative 
when most antibiotics have failed or in cases of allergic reactions to 
those other first-line antibiotics. For these reasons, it is imperative 
that evaluation of the safety and quality of the drug be done 
especially in this part of the world where adequate measures do not 
exist for proper management and storage of medications as 
specified in the official books [1]. Most drugs are not properly stored 
after they have left the manufacturers - they may be exposed to 
adverse conditions during shipping and when in possession of 
distributors and consumers, so much so that when it gets to the end 
users it may become ineffective and does not meet its therapeutic 
requirements. Therefore, frequent post market surveillance of drugs 
such as that undertaken in this study are crucial to protect public 
health especially in developing countries where counterfeit and 
substandard drugs have become a major challenge to health care 
services. Post market surveillance or monitoring involves all 
activities undertaken to obtain more data and information about a 
product after it has been granted marketing authorization and made 
available for public use. 
In this study, it was assumed that previous studies must have been 
carried out prior to release of the tablets and so the duration of this 
study was not as long as 6 months as recommended by ICH. 
Hence, this work was carried out basically to confirm the stability of 
the already ‘qualified’ Ciprofloxacin tablets and where necessary, 
give suggestions based on the results obtained. 
Literature survey reveals that several investigations on the 
pharmaceutical quality of Ciprofloxacin tablets after subjection to 
accelerated stability conditions have been carried out, mainly with 
respect to the dissolution profiles and content uniformity. Certainly, 
numerous studies have been conducted on this drug, since it is one 
of the most prescribed antibiotics and the incessant saturation of 
the therapeutic markets with different formulations of Ciprofloxacin. 
Hence, the need for such extensive studies. However, none of 
these investigations has been reported with respect to the other 
quality control parameters used to assess the stability of a solid oral 
drug dosage form such as hardness, disintegration, uniformity of 
weight, all of which are employed in this study to evaluate the 
stability of the Ciprofloxacin tablets that have been subjected to 
accelerated storage conditions such as sunlight, UV light, 
temperature and moisture. These quality control tests are equally 
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important and necessary in evaluation of tablets especially with 
regards to the physical and chemical stability of drugs. 
Also this research work is unique because whilst the two 
temperature and humidity are the basic conditions required to carry 
out such stability studies as stated by ICH guidelines, this study 
includes two more stress conditions such as exposure of the tablets 
to both sunlight and UV light. Stability studies should include testing 
of the attributes of those drug substance that are susceptible to 
change.” In this case, Ciprofloxacin is known for its photo reactivity 
and so inclusion of sunlight and UV light as part of the accelerated 
storage conditions gives an added advantage. 
 
Materials and Method 
 
Reagents and samples 
 
Ciprofloxacin hydrochloride tablets (Ciproxamed) purchased from a 
retail pharmacy outlet in Nigeria containing 500 mg Ciprofloxacin 
Hydrochloride, Pharmaceutical grade ciprofloxacin powder from 
ACT GEN pharma, India, analytical grade hydrochloric acid, distilled 
water. All tests were performed within products’ expiration dates.  
 
Apparatus and Equipment 
 
ERWEKA hardness tester (Model-TBH 100), ERWEKA dissolution 
apparatus (Model-DT 600), ACCULAB ALC-210.4 electronic 
balance, ERWEKA disintegration tester-ZT x 20, JENWAY 6405 
UV/VIS spectrophotometer, volumetric flasks, glass test tubes, 
glass funnels, beakers, measuring cylinders, thermometers, oven. 
 
Method 
 
The following quality control parameters were employed in the 
assay- weight uniformity, tablet hardness, disintegration, dissolution 
and content of active ingredient tests according to specifications 
given in both the British Pharmacopoeia (BP) 2012 and United 
States Pharmacopoeia (USP) 200. The materials were tested at 
established time intervals with specific methods of assay in order to 
distinguish the degradation from inter assay variation.  
 
Exposure to the accelerated stress conditions 
 
The Ciprofloxacin tablets (equivalent to 500 mg of Ciprofloxacin 
hydrochloride) were exposed to the following stress conditions:- 
TEMPERATURE: The ciprofloxacin tablets (700 tablets equivalent 
to 70 packs as they come in a pack of 10 tablets) were kept at 40 ± 
10C in an oven for a total of 45 days. Samples from this batch of the 
ciprofloxacin tablets were taken at 4-day intervals; on days 0, 4, 8, 
12, 16, 20, 24, 28, 32, 36, 40, 44 and analyzed using these quality 
control tests-uniformity of weight, hardness, disintegration, content 
of active ingredient and dissolution test. 
SUNLIGHT: 700 ciprofloxacin tablets were exposed to adequate 
sunlight in clean and dry glass trays without being affected by 
rainfall and moisture for a total of 45days. Samples were taken at 4-
day intervals as described above and the same quality control tests 
mentioned above were carried out on these samples. 
MOISTURE: 700 ciprofloxacin tablets were kept shielded from 
sunlight but properly exposed to moisture in the environment, with a 
relative humidity of about 75% for a period of 45 days in total. 
Samples were taken at 4-day intervals as described above and the 
same quality control tests were used to evaluate the stability of the 
tablets after exposure to this stress condition. 
UV LIGHT: 700 ciprofloxacin tablets were exposed for 4 hours each 
day to UV light of 365 nm for a total of 45 days. Again, as with the 
other stress conditions mentioned above, samples were taken at 4-
day intervals and the same quality control tests were carried out on 
those samples to evaluate their stability after exposure to the stress 
condition. 
 
Preparation of standard stock solution 
 
Standard solution of Ciprofloxacin hydrochloride was prepared by 
accurately weighing 10 mg of pharmaceutical grade Ciprofloxacin 
hydrochloride powder and dissolving in 50 ml of distilled water in a 
50 ml volumetric flask to obtain a stock solution of 200 µg/ml. 
1 ml of this solution was transferred to another volumetric flask and 
diluted to 10 ml to get a 20 µg/ml solution. 
 
Determination of wavelength of maximum absorption 
 
The 20 µg/ml solution prepared as described above was scanned in 
the UV spectrophotometer in the range of 260-280 nm and the 
wavelength of maximum absorption (lambda max) was found to be 
275 nm. 
 
Determination of standard curve (Beer’s calibration 
curve) 
 
From the 20 µg/ml stock solution, other concentrations were derived 
by conducting serial dilutions whereby 1 ml, 2 mls, 3 mls, 4 mls, 5 
mls, 6 mls, 7 mls, 8 mls, 9 mls were withdrawn from the 20 µg/ml 
solution and diluted to 10 mls each time with distilled water to give 
their respective concentrations- 2, 4, 6, 8, 10, 12, 14, 16, 18 µg/ml. 
These solutions of different known concentrations were scanned at 
275 nm using UV spectrophotometer and their absorbance gotten. 
This was done in triplicates for each concentration. 
The calibration curve was plotted as concentration against 
absorbance mean to generate an equation:  
y = mx.                                    (1) 
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Content of active ingredient 
 
Every fourth day, twenty tablets in total are randomly selected from 
each of the above stated stress conditions, weighed individually and 
the mean weight calculated. The tablets are crushed to a fine 
powder and the mean weight is collected into a 500 ml volumetric 
flask and dissolved in distilled water up to 500 ml mark. 1 ml of this 
solution is withdrawn into a 100 ml volumetric flask and further 
diluted to 100 ml. 5 ml of this second solution is then scanned in the 
UV spectrophotometer at 275 nm to get its absorbance.  The y = mx 
equation generated from the calibration curve (where y refers to 
response, m-the slope and x-concentration) was used in quantifying 
the actual concentration of ciprofloxacin hydrochloride present in 
each drug sample solution. Hence the amount of Ciprofloxacin 
hydrochloride present in each tablet was calculated and compared 
to the label claim. The BP 2009 specifies an acceptable drug 
content range of 98 – 102 %. 
Apart from those methods mentioned in the official books such as 
HPLC, titrimetry, several ways of measuring the content of 
Ciprofloxacin in tablets have been used, such as UV 
spectrophotometry [2-5]. Most of the analytical methods for the 
determination of Ciprofloxacin employ HPLC. It is also the official 
method in the United States, Pharmacopoeia, British 
Pharmacopoeia and Brazilian Pharmacopoeia. But other simple and 
rapid methods such as UV spectrophotometry for the determination 
of ciprofloxacin have been developed and validated through the 
parameters of linearity, accuracy, precision, limit of detection, limit 
of quantitation, specificity, and robustness according to ICH 
guidelines and are described in the literature [6]. This is especially 
important in small laboratories and in places where there are no 
sophisticated and expensive instruments. This method has been 
successfully applied to the determination of Ciprofloxacin in 
solution. This research employs the use of UV spectrophotometry 
which have also been successfully employed in others countries as 
mentioned earlier. Thus, the procedure is suitable for the 
determination of Ciprofloxacin HCL as a routine method with 
adequate accuracy. 
 
Weight uniformity test 
 
This test was performed as described in the British Pharmacopoeia 
(2009). The weight of twenty tablets randomly selected from each of 
the above stated stress conditions were individually weighed using 
an electronic balance. The mean tablet weight and standard 
deviation were calculated. This test was repeated at 4-day intervals 
for each of the stress conditions outlined earlier. 
 
Hardness test 
 
The hardness of 10 tablets selected randomly from each of the 
above mentioned conditions was determined using an ERWEKA 
hardness tester. The mean hardness and standard deviation were 
calculated. The test was repeated at 4-day intervals for each stress 
condition. 
 
Disintegration test 
 
The ERWEKA disintegration test apparatus was used based on the 
British Pharmacopoeia 2009 method. The disintegration medium 
was 0.1N HCl filled to 700 mls in the vessel maintained at 37 ± 
0.50C. Six tablets from each of the above mentioned conditions 
selected randomly were used for the test (which was carried out at 
4-day intervals). The disintegration time was taken as the mean 
time needed for the tablets to break into particles small enough to 
pass through the screen into the disintegration medium. 
 
Dissolution test 
 
ERWEKA dissolution apparatus was used, employing the British 
Pharmacopoeia 2009 method. Vessels containing 900mls of water 
as the dissolution medium were used for this test. The vessels were 
immersed in a circulating water bath maintained at 37±0.50C and 
allowed to equilibrate. Once the desired temperature was attained, 
the tablets were added to the center bottom of the vessel and the 
paddle was rotated at 100 rpm. 10 mls of the dissolution medium 
was withdrawn from each of the vessels using a pipette after 10, 20, 
30, 40, 50 and 60 mins and an equivalent amount of the dissolution 
medium was immediately introduced as a replacement each time. 
The samples were filtered and the actual concentrations were 
determined by measuring the absorbance at 275 nm using a UV 
spectrophotometer. Using the standard curve already prepared with 
the reference standard, the percent of drug released was 
determined for the six tablets obtained from each of the stress 
conditions they were subjected to. The mean was calculated for 
each of the conditions. The test was carried out at 4-day intervals 
for each of the conditions. 
NOTE: All the quality control tests were performed on the 
Ciprofloxacin tablets at day 0, prior to their exposure to the four 
stress conditions outlined earlier, to serve as a baseline so that the 
rate and extent of degradation can be properly monitored or 
determined. 
 
Results and Discussion 
 
A summary of the results of weight uniformity, hardness and content 
of active ingredient, disintegration and dissolution tests are 
presented in Figures 1-7 and Table 1. 
 
Uniformity of weight 
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The tablet weight uniformity for the ciprofloxacin tablets studied are 
within acceptable limits. The British Pharmacopoeia 2012 specifies 
that for tablets weighing 324 mg and above, weights of not more 
than two tablets should deviate from the average weight by more 
than 5 %. Therefore, all the ciprofloxacin tablets exposed to the four 
accelerated storage conditions of temperature, humidity, sunlight 
and UV light passed the test for the period of their exposure 
(throughout the stability study which lasted for 45 days). The 
maximum deviation of 4.08 % occurred amongst those tablets 
exposed to moisture on day 36 of their exposure, yet it still complied 
with the specifications. For the other storage conditions- 
temperature, sunlight, UV light, they had maximum deviations of 
3.16 %, 3.09 % and 2.06 % respectively at the end of the 
evaluation. 
 
Table 1: Results for uniformity of weight of ciprofloxacin hydrochloride tablets subjected to the four accelerated stability conditions (mean weight 
presented in mg) 
DAYS 
 
SUNLIGHT MOISTURE  
-75% RELATIVE HUMIDITY 
TEMPERATURE - 40 ± 10C UV-LIGHT 365nm for 
4hours daily 
0 0.97 ± 0.02   0.97 ± 0.02  0.97 ± 0.02  0.97 ± 0.02 
4 0.97 ± 0.03  0.97 ± 0.01 0.96 ± 0.02 0.97 ± 0.01 
8 0.96 ± 0.02  0.97 ± 0.01 0.96 ± 0.02 0.97 ± 0.01 
12 0.96 ± 0.02 0.97 ± 0.02 0.96 ± 0.01 0.97 ± 0.01 
16 0.96 ± 0.02 0.97 ± 0.02 0.96 ± 0.01 0.97 ± 0.02 
20 0.96 ± 0.02  0.98 ± 0.02 0.95 ± 0.02 0.97 ± 0.02 
24 0.96 ± 0.02  0.98 ± 0.02  0.95 ± 0.02 0.97 ± 0.01 
28 0.96 ± 0.02 0.98 ± 0.03 0.95 ± 0.02 0.97 ± 0.01 
32 0.96 ± 0.02  0.98 ± 0.04 0.95 ± 0.03 0.97 ± 0.01 
36 0.96 ± 0.01 0.98 ± 0.04 0.95 ± 0.01 0.97 ± 0.01 
40 0.96 ± 0.01  0.98 ± 0.03 0.94 ± 0.02 0.97 ± 0.02 
44 0.96 ± 0.01  0.98 ± 0.03 0.94 ± 0.02 0.97 ± 0.02 
Each value represents mean weight ±	standard deviation 
 
There were some significant changes in weight however, especially 
for those tablets subjected to sunlight, moisture and temperature.  A 
decrease in weight was observed with increasing time for those 
tablets exposed to temperature of 40 ± 10Cand sunlight (a slight 
decrease though), while for those subjected to moisture an increase 
in weight was observed. Exposure of the tablets to accelerated 
storage conditions primarily contributes to atmospheric moisture 
absorption as demonstrated by tablet weight gain. Generally, 
uniformity of weight serves as a pointer to good manufacturing 
practices as well as amount of active pharmaceutical ingredient 
contained in the formulation.  
 
Hardness test 
 
The mean values obtained for tablet hardness are also within 
acceptable range. A force of about 4 kg force is the minimum 
requirement for a satisfactory tablet [7]. The ciprofloxacin tablets 
under study passed the hardness test for all the days they were 
subjected to the four accelerated storage conditions as they still had 
a mean hardness of over 4 kg force at the end of the evaluation 
(see figure 1). Hardness test assesses the ability of the tablets to 
withstand handling without fracturing or chipping [7]. It can also 
influence disintegration and hence dissolution because the harder a 
tablet, the more time it takes to disintegrate. Generally, there was a 
decrease in tablet hardness of the ciprofloxacin tablets with time in 
this order Temperature < Moisture < Sunlight < UV light , with those 
exposed to temperature of 40 ± 10Chaving the least value of 4.59 
kg force whilst those exposed to UV light had the highest value of 
7.85 kg force at the end of the evaluation. 
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Figure 1: A plot af mean hardness (kg force) against exposure time (days) for ciprofloxacin tablets subjected to accelerated stability conditions  
 
Disintegration test 
 
The British Pharmacopeia 2012 specifies that for uncoated tablets, 
disintegration time should be within 15 mins. In accordance with this 
the ciprofloxacin tablets exposed to all four accelerated storage 
conditions passed the disintegration test for the period of the study 
(figure 2). 
Those tablets exposed to moisture showed a decrease in 
disintegration time as the number of days increased, starting with a 
mean disintegration time of 1.15 mins on day 0 and ending on day 
44 with a mean disintegration time of 0.40 mins. This was in 
contrast to those tablets exposed to temperature of 40 ± 0C where 
their mean disintegration time increased with increasing number of 
days, starting with a mean disintegration time of 1.15 mins on day 0 
and ending with 3.30 mins on day 44. Those exposed to UV light 
and sunlight had little or no changes in their disintegration time, 
both starting with a mean disintegration time of 1.15 mins on day 0 
and ending on day 44 with 1.09 mins and 1.02 mins respectively. 
Disintegration is a crucial step in drug absorption and could at times 
be directly related to dissolution and bioavailability of a drug. 
Usually, the higher the tablet hardness, the slower the disintegration 
and hence dissolution rate [8]. Therefore, it would have been 
expected that those tablets exposed to UV light which had the 
highest value for hardness after the period of evaluation would also 
have the highest disintegration time and those exposed to 
temperature the fastest. This perceived discrepancy may be as a 
result of the effect of different storage conditions employed, on the 
excipients used in each formulation. 
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Dissolution test 
 
Both the United States Pharmacopoeia 2005 and the British 
Pharmacopoeia 2012 specifies that the amount of drug released 
(dissolution) should not be less than 80% of the labeled amount at 
30 minutes. In the case of the ciprofloxacin tablets under study, the 
label claim is 500 mg which puts 80 % at 400 mg. At time zero (day 
0), the ciprofloxacin tablets had an acceptable dissolution profile – 
releasing 89.12 % of the label claim after 30 mins. However, with 
increasing time there was a gradual reduction in the dissolution rate 
with the tablets exposed to all four storage conditions failing the test 
on day 44 where they had less than 80 % release of the label claim 
(see figures 3-6). The ciprofloxacin tablets exposed to UV light also 
failed the dissolution test from day 36 where they had less than 80 
% release until day 44 of the evaluation. 
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Figure 3: Drug release profile for ciprofloxacin tablets subjected to accelerated stability condition: 
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Dissolution stability is considered a critical parameter not just from 
the standpoint of quality control but also for the impact on 
bioavailability of the product because significant changes of the in 
vitro release profile during storage in different conditions may affect 
its bioavailability. During aging, the absence of dissolution changes 
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condition: uv light of 365nm for 4hours each day  
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provides some assurance that the bioavailabilit
The different excipients of a formulation may interact during 
exposure to high temperature or high humidity thereby reducing the 
in vitro dissolution. It is important to note that exposure of drugs 
which are susceptible, to light initiates many side reaction which 
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may affect the excipients interactions, surface of the formulation, 
drug uniformity and this may affect the dissolution rate profile and 
also bioavailability of the drugs [9]. 
This might explain why those tablets exposed to UV light failed the 
test, days ahead of their counterparts. The tablets exposed to UV 
light had a higher value for hardness than the others and show a 
slower dissolution rate at an earlier time (failing to comply with the 
specifications of 80 % drug release at 30 mins from day 36 of their 
exposure) than those exposed to the other three storage conditions 
(which failed to comply with the specifications of 80 % drug release 
at 30 mins on day 44 of their exposure) thus supporting the 
statement made earlier that, ‘the higher the tablet hardness - the 
slower the drug dissolution rate.’ 
 
Content of active ingredient 
 
The BP specification for content of ciprofloxacin tablet should be 
between 95-105 % [10]. Therefore, only those tablets exposed to 
UV light passed the test for all 44 days as they had a minimum of 
96.83 % content on the 44th day. At day 0, all the tablets assayed 
passed this test, having a ciprofloxacin content of 99.43 %. 
However, those exposed to sunlight and temperature had content of 
ciprofloxacin hydrochloride below 95 % from day 4 which 
progressively declined to 78.36 % and 70.22 % respectively. For 
those exposed to moisture, they passed the test on days 4 - 8 and 
failed the test in subsequent days, having a ciprofloxacin content of 
71.50 % on day 44. Generally, for all the storage conditions, there is 
a decrease in the content of ciprofloxacin hydrochloride after day 0, 
with those exposed to UV light being the least affected. 
 
Conclusion and recommendation 
 
Evaluation of the stability of ciprofloxacin tablets using such tablet 
parameters as hardness, disintegration, dissolution, weight 
uniformity and content of active ingredient tests after subjection to 
accelerated stability conditions showed considerable changes and 
deviations from the normal values obtained prior to exposure of the 
drugs to such stress conditions. For such parameters as hardness, 
disintegration and uniformity of weight, the tablets all remained 
within the specified ranges or complied with the specifications 
stated in the official books throughout the duration of study. As for 
the others- dissolution and content of active ingredient, the tablets 
failed the tests with increasing number of days under such stress 
conditions used in this study. Therefore, these changes noted in 
both the physical and chemical attributes of the ciprofloxacin tablets 
assayed indicates that they are not stable upon exposure to such 
accelerated storage conditions. 
It is recommended that further studies be carried out to characterize 
the degradation products and determine their effect on therapeutic 
efficacy. Also, better approaches should be considered to improve 
the quality and stability of this medication especially with regards to 
packaging to ensure therapeutic efficacy especially in Nigeria where 
the environmental conditions are similar to those conditions used in 
this work. 
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